Globus Medical (GMED) Gets a Hold Rating from Morgan Stanley
In a report released today, David Lewis from Morgan Stanley maintained a Hold rating on Globus Medical (GMED), with a price target of $72.00. The company’s shares closed last Monday at $63.55, close to its 52-week high of $68.24.
According to TipRanks.com, Lewis is a 5-star analyst with an average return of 18.1% and a 75.6% success rate. Lewis covers the Healthcare sector, focusing on stocks such as Axonics Modulation Technologies, Zimmer Biomet Holdings, and Irhythm Technologies.
Globus Medical has an analyst consensus of Moderate Buy, with a price target consensus of $71.91, representing a 13.5% upside. In a report issued on February 18, Oppenheimer also maintained a Hold rating on the stock with a $67.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $68.24 and a one-year low of $33.41. Currently, Globus Medical has an average volume of 536K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Globus Medical, Inc. operates as a medical device company that develops and commercializes healthcare solutions. The firm engages in developing products that promote healing in patients with musculoskeletal disorders. It classifies products into Innovative Fusion and Disruptive Technology. It operates through the United States and International geographical segments. The company was founded by David C. Paul, David D. Davidar and Andrew Iott in March 2003 and is headquartered in Audubon, PA.